Brief: Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial Of Anavex®3-71 In Schizophrenia
16/01/2024 12:33
Jan 16 (Reuters) - Anavex Life Sciences Corp AVXL.O :
* ANAVEX LIFE SCIENCES ANNOUNCES U.S. PHASE 2 CLINICAL TRIAL
OF
ANAVEX®3-71 IN SCHIZOPHRENIA
* ANAVEX LIFE SCIENCES CORP - PLACEBO-CONTROLLED PHASE 2
TRIAL
CLEARED BY FDA - TRIAL TO BEGIN IN Q2 2024
* ANAVEX LIFE SCIENCES CORP - PLACEBO-CONTROLLED PHASE 2
TRIAL
CLEARED BY FDA - TRIAL TO BEGIN IN Q2 2024
Source text for Eikon: ID:nGNX1YP1S3
Further company coverage: AVXL.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Anavex Life Sciences
See all newsBrief: Anavex Provides Corporate Update, Announces Completion Of Clinical Conduct Of Adme And Ddi Clinical Studies
Brief: Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome
Brief: Glass Lewis Recommends Anavex Stockholders To Vote For PVG’s Director Nominees
Brief: PVG Calls For Replacing Anavex Board, Hiring "Experienced" CEO
Brief: Pvg Asset Management- Nominates Six Director Candidates For Anavex Board